476 results on '"Blackwell, K."'
Search Results
2. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
3. Clinical Trial Results Summary for Laypersons: A User Testing Study
4. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
5. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
6. Calcium: Amplitude, Duration, or Location?
7. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
8. Magnetic Resonance Imaging of the Head and Neck
9. Cellular Mechanisms of Calcium Elevation Involved in Long Term Memory
10. Effect of Potassium Conductance Characteristics on Pattern Matching in a Model of Dendritic Spines
11. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
12. Analysis of dermatologic events in patients with cancer treated with lapatinib
13. Modulation of atrial contraction by PKA and PKC during the compensated phase of eccentric cardiac hypertrophy
14. Cadmium accumulation and its effects on intracellular ion pools in a brewing strain of Saccharomyces cerevisiae
15. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
16. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
17. The prevalence of stress urinary incontinence in patients with cystic fibrosis: an under-recognized problem
18. Manganese uptake and toxicity in magnesium-supplemented and unsupplemented Saccharomyces cerevisiae
19. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
20. The Confounded Nature of Angry Men and Happy Women
21. Metal cation uptake by yeast: a review
22. Paired Turbulence and Light do not Produce a Supralinear Calcium Increase in Hermissenda
23. The prevalence of urinary and fecal incontinence in children with cystic fibrosis
24. Regulation of insulin-like growth factor-1 by the renin–angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist
25. Pattern-recognition by an artificial network derived from biologic neuronal systems
26. Performance comparison of a neural network with human observers on a visual target detection task
27. Evidence for a Distinct Light-Induced Calcium-Dependent Potassium Current in Hermissenda Crassicornis
28. Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
29. Abstract P1-06-04: Small-molecule screening nominates diverse combination therapies that sensitize BRCA mutant and wild-type triple negative breast cancer to PARP inhibition
30. Abstract P6-10-01: Incidence and mortality among breast cancer patients < 40 years old: U.S. trends from 1992-2014
31. Abstract OT3-04-02: The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
32. Abstract P6-09-03: Gene expression patterns in younger versus older HR+ breast cancer patients: An age-related analysis of HoxB13/IL17BR (H/I), proliferation status, and quantitative hormone receptor expression
33. EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
34. Abstract OT2-01-17: A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
35. Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients
36. Abstract P2-11-05: Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer: Pooled analysis of two randomized, double-blind, phase III trials
37. Regulation of Axon Growth by Alpha 7 Nicotinic Receptor Calcium Transients at the Growth Cone
38. breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
39. METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
40. Abstract P1-10-01: A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (PROTECT1)
41. Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study
42. Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)
43. Abstract OT2-01-02: Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3
44. AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome
45. Multimodal Plasticity in Dorsal Striatum While Learning a Lateralized Navigation Task
46. Calcium-dependent inactivation of calcium channels in the medial striatum increases at eye opening
47. Desynchronization of Fast-Spiking Interneurons Reduces -Band Oscillations and Imbalance in Firing in the Dopamine-Depleted Striatum
48. Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases
49. 323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
50. Head and neck: Editorial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.